RxDoctor Payments Data

Courtney Cape, OD

Optometrist · San Diego, CANPI 1427673680

Payments from drug & device makers

$2,577in general payments, 2019–2025

Across 65 payments — averaging $39.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$449
  • Amgen$390
  • Alcon$280
  • AbbVie$274
  • Harrow Eye, LLC$245
  • Ocular Therapeutix, Inc.$243
  • plus $696 from 8 others

What the payments were for

  • Food & beverage$2,577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,577 in reported general payments places this provider in the 80th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$18,406
Medicare patients
91
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner61$120,478
XiidraLifitegrast66$109,946
RestasisCyclosporine87$90,762
LumiganBimatoprost196$87,216
TyrvayaVarenicline Tartrate12$10,356
Cyclosporine13$3,553
Brimonidine Tartrate26$2,601
Loteprednol Etabonate18$2,528
Latanoprost249$2,333
Timolol Maleate170$1,746
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$1,514
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat140$1,297
Prednisolone Acetate33$1,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$274$177,979283 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$449$120,47861 claims
Bausch & Lomb Americas Inc.Xiidra$188$109,94666 claims
Oyster Point Pharma, Inc.Tyrvaya$171$10,35612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,778 optometrist providers in California.

Other optometrist in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →